Drug Type Bispecific antibody |
Synonyms BIS5, LB1410, LNL005 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenosquamous Carcinoma | Phase 2 | China | 27 Aug 2025 | |
Cervical Squamous Cell Carcinoma | Phase 2 | China | 27 Aug 2025 | |
Uterine Cervical Cancer | Phase 2 | China | 27 Aug 2025 | |
Uterine Cervix Adenocarcinoma | Phase 2 | China | 27 Aug 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 19 Jun 2024 | |
Bile Duct Neoplasms | Phase 2 | China | 19 Jun 2024 | |
Endometrial Carcinoma | Phase 2 | China | 19 Jun 2024 | |
Endometrioid Carcinoma | Phase 2 | China | 19 Jun 2024 | |
ER Positive Endometrial Carcinoma | Phase 2 | China | 19 Jun 2024 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | China | 19 Jun 2024 |
Phase 1 | 79 | xcjdlhlaej(fehizwfvrj) = 24.1% thaiakcleo (mkjcehmiaa ) View more | Positive | 30 May 2025 | |||
Phase 1 | - | tqfhlsinex(gerbdpmpey) = aiakprdjjh ugtmfwaqzu (rgfxfikrwn ) View more | - | 02 Jun 2022 | |||
PD-1 antibody | tqfhlsinex(gerbdpmpey) = mtnmzycjrd ugtmfwaqzu (rgfxfikrwn ) View more |